Effective therapy of enteric hyperoxaluria: in vitro binding of oxalate by anion-exchange resins and aluminum hydroxide.
Hyperabsorption of dietary oxalate is a major factor in the pathogenesis of enteric hyperoxaluria and a frequent complication of inflammatory bowel disease and ileojejunal bypass surgery. Successful treatment requires reduction in oxalate intake or inhibition of absorption of dietary oxalate by oral ingestion of oxalate binding agents. To identify such agents, oxalate binding by anion-exchange resins, gums, and aluminum hydroxide was measured under conditions that simulated those present in the intestinal lumen. Of the agents tested, those that bound oxalate best were colestipol and aluminum hydroxide. Strongly basic anion-exchange resins readily bound oxalate only in the absence of chloride. These results suggest that colestipol and aluminum hydroxide administration might reduce dietary oxalate absorption in patients with enteric hyperoxaluria.
D000327:Adsorption; D000536:Aluminum Hydroxide / Q000493:pharmacokinetics* / Q000627:therapeutic use; D006959:Hyperoxaluria / Q000188:drug therapy* / Q000378:metabolism; D007475:Ion Exchange Resins / Q000493:pharmacokinetics* / Q000627:therapeutic use; D010070:Oxalates / Q000493:pharmacokinetics*; D019815:Oxalic Acid; D013816:Thermodynamics
D007475:Ion Exchange Resins; D010070:Oxalates; D000536:Aluminum Hydroxide; D019815:Oxalic Acid